MCID: CLR003
MIFTS: 56

Clear Cell Adenocarcinoma malady

Category: Cancer diseases

Aliases & Classifications for Clear Cell Adenocarcinoma

About this section

Aliases & Descriptions for Clear Cell Adenocarcinoma:

Name: Clear Cell Adenocarcinoma 11 13
Mesonephroma 11 39 68
Water-Clear Cell Adenocarcinoma 11 68
Adenocarcinoma, Clear Cell 39 68
Mesonephroid Clear Cell Carcinoma 11
Clear Cell Adenocarcinoma Nos 11
Water-Clear Cell Carcinoma 11
 
Adenocarcinoma Clear Cell 50
Mesonephroma, Malignant 11
Wolffian Duct Neoplasm 11
Malignant Mesonephroma 11
Mesonephric Tumor 68
Mesonephroma Nos 11

Classifications:



Summaries for Clear Cell Adenocarcinoma

About this section
Wikipedia:71 Clear-cell adenocarcinoma is a type of adenocarcinoma that shows clear cells. more...

MalaCards based summary: Clear Cell Adenocarcinoma, also known as mesonephroma, is related to bladder clear cell adenocarcinoma and ovarian clear cell adenocarcinoma. An important gene associated with Clear Cell Adenocarcinoma is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways are NTHi-Induced Signaling and Androgen receptor signaling pathway. Affiliated tissues include cervix, ovary and colon, and related mouse phenotypes are Decreased viability in esophageal squamous lineage and craniofacial.

Disease Ontology:11 An adenocarcinoma that derives from epithelial cells which have clear cytoplasm.

Related Diseases for Clear Cell Adenocarcinoma

About this section

Diseases related to Clear Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 122)
idRelated DiseaseScoreTop Affiliating Genes
1bladder clear cell adenocarcinoma33.4ESR1, TP53
2ovarian clear cell adenocarcinoma12.2
3cervical clear cell adenocarcinoma12.1
4endometrial clear cell adenocarcinoma12.1
5clear cell adenocarcinoma of ovary12.1
6fallopian tube clear cell adenocarcinoma12.1
7urethra clear cell adenocarcinoma12.0
8uterine ligament clear cell adenocarcinoma12.0
9ampulla of vater clear cell adenocarcinoma12.0
10bile duct clear cell adenocarcinoma12.0
11bladder tubulo-cystic clear cell adenocarcinoma12.0
12bladder papillary clear cell adenocarcinoma12.0
13bladder diffuse clear cell adenocarcinoma11.9
14wolffian duct adenoma11.0
15multilocular cystic clear cell renal cell neoplasm of low malignant potential10.9
16adenocarcinoma10.9
17vaginitis10.4
18endometriosis10.4
19malt worker's lung10.3KLK3, TP53
20mitochondrial neurogastrointestinal encephalopathy disease10.3SMAD4, TP53
21urethritis10.2
22fallopian tube germ cell cancer10.2ARID1A, HNF1B, SMAD3
23iris spindle cell melanoma10.2AMACR, KLK3, SMAD4
24familial hypopituitarism10.2SMAD4, TP53
25x-linked leigh syndrome10.2ESR1, SMAD4
26tmem70 defect10.2PAX8, TP53
27steroid-induced glaucoma - borderline10.2KLK3, KRT20
28splenic infarction10.1AMACR, KLK3, TP53
29perinatal jaundice due to hepatocellular damage10.1ARID1A, ESR1, HNF1B
30congenital bile acid synthesis defect10.1ESR1, KLK3, TP53
31adult medulloblastoma10.1AMACR, KLK3, TP53
32necrobiosis lipoidica10.1ESR1, KLK3, TP53
33acute necrotizing encephalitis10.1KLK3, SMAD2, SMAD3
34neuroectodermal endocrine syndrome10.1SMAD2, SMAD3, SMAD4
35extramedullary plasmacytoma10.1KLK3, KRT20
36urethral diverticulum10.1
37small intestine leiomyoma10.1KRT20, TP53
38clear cell hidradenoma10.1KRT20, TP53
39nevoid hypermelanosis, linear and whorled10.1ESR1, KLK3, TP53
40cervicitis10.1
41spiradenoma10.1KRT20, TP53
42trachea squamous cell carcinoma10.1ARID1A, ESR1, TP53
43fuchs' heterochromic uveitis10.1AMACR, KLK3, PAX8
44villoglandular endometrial endometrioid adenocarcinoma10.1ESR1, TP53
45congenital pulmonary airway malformation10.1HNF1B, PAX2
46rhizomelic chondrodysplasia punctata spectrum10.1HNF1B, PAX2
47cervix endometriosis10.1AMACR, KRT20
48subareolar duct papillomatosis10.1ESR1, PAX8
49placental site trophoblastic tumor10.1KRT20, SMAD4, TP53
50papillary transitional carcinoma10.1KLK3, KRT20, TP53

Graphical network of the top 20 diseases related to Clear Cell Adenocarcinoma:



Diseases related to clear cell adenocarcinoma

Symptoms & Phenotypes for Clear Cell Adenocarcinoma

About this section

GenomeRNAi Phenotypes related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00235-A6.8ARID1A, ESR1, HNF1B, KLK3, PAX8, SMAD3

MGI Mouse Phenotypes related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

41 (show all 18)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053828.1ARID1A, PAX8, PTHLH, SMAD2, SMAD3, SMAD4
2MP:00020068.1ARID1A, ESR1, SMAD2, SMAD3, SMAD4, TP53
3MP:00053718.0ESR1, PAX8, PTHLH, SMAD3, SMAD4, TP53
4MP:00053817.7ESR1, PTHLH, SMAD2, SMAD3, SMAD4, TP53
5MP:00053917.7ARID1A, PAX2, PAX8, PTHLH, SMAD2, SMAD3
6MP:00053677.3ESR1, HNF1B, PAX2, PAX8, PTHLH, SMAD3
7MP:00053707.1AMACR, ESR1, HNF1B, SMAD2, SMAD3, SMAD4
8MP:00053877.1ARID1A, ESR1, HNF1B, PTHLH, SMAD2, SMAD3
9MP:00053907.0ARID1A, ESR1, PAX8, PTHLH, SMAD2, SMAD3
10MP:00053806.7ARID1A, ESR1, HNF1B, PAX2, PAX8, SMAD2
11MP:00053896.7ARID1A, ESR1, PAX2, PAX8, PTHLH, SMAD2
12MP:00053846.5ARID1A, ESR1, PAX2, PAX8, PTHLH, SMAD2
13MP:00053856.4ARID1A, ESR1, PAX2, PAX8, PTHLH, SMAD2
14MP:00053766.3AMACR, ARID1A, ESR1, HNF1B, PAX8, PTHLH
15MP:00036316.3ARID1A, ESR1, PAX2, PAX8, PTHLH, SMAD2
16MP:00053786.2AMACR, ARID1A, ESR1, HNF1B, PAX8, PTHLH
17MP:00053796.0ARID1A, ESR1, HNF1B, PAX2, PAX8, PTHLH
18MP:00107685.8AMACR, ARID1A, ESR1, HNF1B, PAX2, PAX8

Drugs & Therapeutics for Clear Cell Adenocarcinoma

About this section

Drugs for Clear Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 288)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Sunitinibapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1510341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
2
Bevacizumabapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 12020216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
3
AldesleukinapprovedPhase 4, Phase 2, Phase 1, Early Phase 140585898-30-2, 110942-02-4
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
 
Interleukin-2 aldesleukin
Interleukin-2(2-133),125-ser
Recombinant interleukin-2 human
4
Axitinibapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1109319460-85-06450551
Synonyms:
319460-85-0
790713-39-2
AC-1539
AC1O51X3
AG 013736
AG-013736
AG-013736, Axitinib
AG-13736
AG013736
Axitinib
C503983
CID6450551
 
EC-000.2322
I14-1971
INLYTA
Inlyta
MolPort-006-392-413
N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide
N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
S1005_Selleck
ST51054130
UNII-C9LVQ0YUXG
ZINC03816287
axitinib
axitinibum
5
nivolumabapprovedPhase 4, Phase 3, Phase 2, Phase 1424946414-94-4
Synonyms:
BMS-936558
 
MDX-1106
ONO-4538
nivolumab
6Angiogenesis Modulating AgentsPhase 4, Phase 3, Phase 2, Phase 14185
7Protein Kinase InhibitorsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 13689
8Angiogenesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 14257
9Interleukin-2Phase 4, Phase 2, Phase 1, Early Phase 1571
10Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 122062
11Anti-HIV AgentsPhase 4, Phase 2, Phase 1, Early Phase 13162
12Anti-Retroviral AgentsPhase 4, Phase 2, Phase 1, Early Phase 13296
13Antiviral AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 19967
14AntibodiesPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 16394
15Antibodies, MonoclonalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14039
16ImmunoglobulinsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 16394
17Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 123689
18AnalgesicsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 111733
19Analgesics, Non-NarcoticPhase 4, Phase 2, Phase 1, Early Phase 16501
20
EtoposideapprovedPhase 3, Phase 2, Phase 1126933419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
 
Eposin, Vepesid, VP-16, Toposar, Etoposide
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide
21
Paclitaxelapproved, vet_approvedPhase 3, Phase 2, Phase 1286433069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
22
Vincristineapproved, investigationalPhase 3, Phase 29222068-78-2, 57-22-75978
Synonyms:
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
CHEBI:28445
CID5978
D08679
DB00541
EINECS 200-318-1
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
LS-228
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
Marqibo
NCGC00163700-01
NCI-C04864
NCI60_026703
NSC-67574
Onco TCS
 
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristina
Vincristina [DCIT]
Vincristine (INN)
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristine [INN:BAN]
Vincristinum
Vincristinum [INN-Latin]
Vincrstine
Vincrystine
Vinkristin
Z-D-Val-Lys(Z)-OH
vincristine
23
Oxaliplatinapproved, investigationalPhase 3, Phase 2146061825-94-35310940, 9887054, 6857599, 9887054, 43805
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
 
Oxalatoplatinum
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
oxaliplatine
oxaliplatino
oxaliplatinum
24
Capecitabineapproved, investigationalPhase 3, Phase 21342154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
25
Doxorubicinapproved, investigationalPhase 3, Phase 2, Phase 1175123214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
26
DactinomycinapprovedPhase 3, Phase 24850-76-02019, 457193
Synonyms:
(- )-actinomycin d
(-)-actinomycin d
-pentone
01815_FLUKA
1H-Pyrrolo(2,1-1)-(1,4,7,10,13)oxatetraazacyclohexadecine
2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-I)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide
4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide
50-76-0
A1410_SIGMA
A4262_SIGMA
A9415_SIGMA
AC1L1CQX
AC1L9W52
ACT
ACT D
ACTINOMYCIN D
ACTINOMYCIN D AMP
ACTINOMYCIN-D
ACTO-D
ACon0_000471
ACon1_001004
AD
AD (VAN)
AI3-26374
ActD
Actactinomycin A IV
Actactinomycin a Iv
Actinomycin 11 Cosmegen
Actinomycin 11 cosmegen
Actinomycin 7
Actinomycin A IV
Actinomycin Aiv
Actinomycin C (sub1)
Actinomycin C(sub1)
Actinomycin C1
Actinomycin D
Actinomycin D (JP15)
Actinomycin D deriv. of 3H-phenoxaocardazine
Actinomycin D, sodium deoxyribonucleic acid complex
Actinomycin I
Actinomycin I (sub1)
Actinomycin I(sub 1)
Actinomycin I(sub1)
Actinomycin I1
Actinomycin IV
Actinomycin Iv
Actinomycin X 1
Actinomycin X1
Actinomycin iv
Actinomycin-(threo-val-pro-sar-meval)
Actinomycin-?IV
Actinomycin-[threo-val-pro-sar-meval]
Actinomycindioic D Acid, Dilactone
Actinomycindioic D acid, dilactone
Acto-D
Antibiotic From Streptomyces Parvullus
Antibiotic from Streptomyces parvullus
BCBcMAP01_000155
BRD-A42383464-001-02-2
Bio1_000342
Bio1_000831
Bio1_001320
C06770
C1
C62H86N12O16
CBiol_002056
CCRIS 9
CHEBI:123721
CHEBI:27666
CHEMBL1554
CHEMBL427947
CID2019
 
CID457193
COSMEGEN (TN)
CPD000469227
Chounghwamycin B
Cosmegen
D Actinomycin
D00214
DACTINOMYCIN
DB00970
DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA
Dactinomicina
Dactinomicina [INN-Spanish]
Dactinomycin
Dactinomycin (USP)
Dactinomycin D
Dactinomycin [USAN:BAN]
Dactinomycine
Dactinomycine [INN-French]
Dactinomycinum
Dactinomycinum [INN-Latin]
Dilactone Actinomycin D Acid
Dilactone Actinomycindioic D Acid
Dilactone actin omycindioic D acid
Dilactone actinomycin D acid
Dilactone actinomycindioic D acid
EINECS 200-063-6
FT-0080366
GNF-PF-1977
HBF 386
HBF 386 Meractinomycin
HBF 386 meractinomycin
HMS2052O17
HSDB 3220
LMPK14000005
LS-142
Lyovac Cosmegen
Lyovac cosmegen
MEGxm0_000350
MLS001424196
Meractinomycin
MolPort-001-739-741
MolPort-003-925-177
NCGC00025059-02
NCGC00090796-01
NCGC00161622-01
NCGC00161622-02
NCGC00169767-01
NCI-C04682
NCI60_030539
NP-005932
NSC 3053
NSC-3053
NSC191297
NSC3053
Neuro_000003
Oncostatin K
Oxamide
PXZ-THR-DVA-PRO-SAR-MVA-THR-DVA-PRO-SAR-MVA
SAM001246846
SMP1_000005
SMR000469227
UNII-1CC1JFE158
UPCMLD-DP055
UPCMLD-DP055:001
UPCMLD-DP055:002
WLN: 16- AN FVN IVN LVO PVM SVTJ G1 J1 KY1&1 N1 RY1&1
X 97
actd
actinomycin D
actinomycin cl
actinomycin x i
actinomyein-theo-val-pro-sar-meval
dactinomyein d
o)-(1-oxo-1,2-ethanediyl)]bis(N-methyl)L-valine
27
Sirolimusapproved, investigationalPhase 3, Phase 2, Phase 1194053123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
28
Cyclophosphamideapproved, investigationalPhase 3, Phase 2, Phase 1293550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
29
EverolimusapprovedPhase 3, Phase 2, Phase 11940159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
30
CarboplatinapprovedPhase 3, Phase 2, Phase 1205041575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
31
Miconazoleapproved, investigational, vet_approvedPhase 3, Phase 2, Phase 1370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
32
Sorafenibapproved, investigationalPhase 3, Phase 2, Phase 1700284461-73-0216239, 406563
Synonyms:
284461-73-0
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
AB1004622
AC-1674
AC1L50CF
BAX
BAY 43-9006
BAY 43-9006 (free base)
BAY 43-9006 tosylate salt
BAY 439006
BAY 54-9085 (tosylate salt)
BAY-43-0006
BAY-43-9006
BAY-54-9085
BAY43-9006
BRD-K23984367-001-01-8
Bio-0100
CHEBI:47228
CHEBI:50924
CHEMBL1336
CID216239
 
D08524
DB00398
DB07438
EN002709
I06-0856
K00597a
Kinome_766
LS-186067
LS-187021
LS-187788
MolPort-003-850-270
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
NCGC00167488-01
NSC-724772
NSC747971
Nexavar
STK627350
Sorafenib
Sorafenib (INN)
Sorafenib [INN]
Sorafenib tosylate
Sorafenibum
UNII-9ZOQ3TZI87
ZINC01493878
nchembio.117-comp17
sorafenib
sorafenibum
33
SulfamethoxazoleapprovedPhase 3161723-46-65329
Synonyms:
129378-89-8
3-(Para-Aminophenylsulphonamido)-5-methylisoxazole
3-(p-Aminobenzenesulfonamido)-5-methylisoxazole
3-(p-Aminophenylsulfonamido)-5-methylisoxazole
3-(para-Aminophenylsulphonamido)-5-methylisoxazole
3-Sulfanilamido-5-methylisoxazole
3-Sulphanilamido-5-methylisoxazole
4-Amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide
4-Amino-N-(5-methyl-3-isoxazolyl)-Benzenesulfonamide
4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide
4-Amino-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide
4-Amino-N-[5-methyl-3- isoxazolyl]benzenesulfonamide
4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide
4-amino-N-(5-methylisoxazol-3-yl)benzenesulfonamide
46850_RIEDEL
5-Methyl-3-sulfanilamidoisoxazole
5-Methyl-3-sulfanylamidoisoxazole
5-Methyl-3-sulfonylamidoisoxazole
5-Methyl-3-sulphanil-amidoisoxazole
723-46-6
A047
AB00052099
AC-11118
AC1L1K42
AC1Q2J5R
AKOS000200952
ALBB-002089
ARONIS018156
Apo-Sulfamethoxazole
Azo Gantanol
Azo-Gantanol
Azo-gantanol
BAS 00836086
BB_SC-1251
BIDD:GT0731
BPBio1_000081
BRD-K28494619-001-05-0
BRN 0226453
BSPBio_000073
BSPBio_002028
Bactrim
Bactrimel
C07315
C10H11N3O3S
CAS-723-46-6
CCRIS 567
CHEBI:9332
CHEMBL443
CID5329
CPD000058223
D00447
D013420
DB01015
DivK1c_000649
EINECS 211-963-3
Gamazole
Gantanol
Gantanol (TN)
Gantanol (tn)
Gantanol-DS
HMS1568D15
HMS1921A21
HMS2092K03
HMS502A11
HMS561O18
HSDB 3186
I01-0154
IDI1_000649
InChI=1/C10H11N3O3S/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6H,11H2,1H3,(H,12,13)
KBio1_000649
KBio2_001474
KBio2_004042
KBio2_006610
KBio3_001528
KBioGR_000749
KBioSS_001474
LS-1620
MLS000069732
MLS001055354
MLS001074165
MS 53
Maybridge1_007190
Metoxal
MolPort-000-145-787
N'-(5-Methyl-3-isoxazole)sulfanilamide
 
N'-(5-Methyl-3-isoxazolyl)-Sulfanilamide
N'-(5-Methyl-3-isoxazolyl)sulfanilamide
N'-(5-Methylisoxazol-3-yl)sulphanilamide
N(Sup1)-(5-Methyl-3-isoxazolyl)sulfanilamide
N(sup 1)-(5-Methyl-3-isoxazolyl)sulfanilamide
N(sup 1)-(5-Methyl-3-isoxazolyl)sulphanilamide
N(sup1)-(5-Methyl-3-isoxazolyl)sulfanilamide
N1-(5-Methyl-3-isoxazolyl)sulfanilamide
N1-(5-Methyl-3-isoxazolyl)sulphanilamide
N1-(5-Methylisoxazol-3-yl)sulfanilamide
N1-(5-methyl-3-isoxazolyl)-Sulfanilamide
NCGC00016533-01
NCGC00016533-02
NCGC00021995-03
NCGC00021995-04
NCGC00021995-05
NINDS_000649
NSC 147832
NSC147832
N^1-(5-Methyl-3-isoxazolyl)-Sulfanilamide
Ndimethyl1-(5-methyl-3-isoxazolyl)-Sulfanilamide
Oprea1_114486
Oprea1_285680
Prestwick0_000177
Prestwick1_000177
Prestwick2_000177
Prestwick3_000177
Prestwick_453
Radonil
Ro 4-2130
Ro 6-2580/11
Ro-4-2130
S0361
S1915_Selleck
S7507_FLUKA
S7507_SIGMA
SAM002554930
SIM
SMR000058223
SMX
SPBio_000896
SPBio_001994
SPECTRUM1500550
STK007988
SULFAMETHOXAZOLE (8064-90-2 (TRIMETHOPRIM/SULFAMETHOXAZOLE)
Septran
Simsinomin
Sinomin
Solfametossazolo
Solfametossazolo [DCIT]
Spectrum2_000788
Spectrum3_000584
Spectrum4_000345
Spectrum5_000982
Spectrum_000994
Sulfamethalazole
Sulfamethoxazol
Sulfamethoxazole
Sulfamethoxazole (JP15/USP/INN)
Sulfamethoxazole [USAN:INN:JAN]
Sulfamethoxazole sodium
Sulfamethoxazole(USAN)
Sulfamethoxazolum
Sulfamethoxazolum [INN-Latin]
Sulfamethoxizole
Sulfamethylisoxazole
Sulfametoxazol
Sulfametoxazol [INN-Spanish]
Sulfanilamide, N1-(5-methyl-3-isoxazolyl)- (8CI)
Sulfisomezole
Sulpha-Methoxizole
Sulpha-methoxizole
Sulphamethalazole
Sulphamethoxazol
Sulphamethoxazole
Sulphamethoxazole BP 98
Sulphamethylisoxazole
Sulphisomezole
TL8005058
TMP/SMX (MIXTURE))
Trib
UNII-JE42381TNV
Urobak
WLN: T5NOJ C1 EMSWR DZ
ZINC00089763
nchembio.221-comp24
sulfamethoxazole
34
Fentanylapproved, illicit, investigational, vet_approvedPhase 3821437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
1-phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl CII
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
 
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
35
Trimethoprimapproved, vet_approvedPhase 3177738-70-55578
Synonyms:
2,4-Diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine
46984_FLUKA
46984_RIEDEL
5-[(3,4,5-Trimethoxyphenyl)methyl]-2,4-pyrimidinediamine
738-70-5
92131_FLUKA
92131_SIGMA
AB00052118
AB1004879
AC-13572
AC1L1KNQ
AC1Q48DF
AI3-52594
AKOS001650069
ARONIS24118
AZT + TMP/SMX (mixture) combination
Abacin
Abaprim
Alcorim-F
Alprim
Anitrim
Antrima
Antrimox
Apo-Sulfatrim
BB_SC-2116
BIDD:GT0190
BPBio1_000215
BRD-K07208025-001-06-5
BRN 0625127
BSPBio_000195
BSPBio_002245
BW 56-72
BW 5672
BW-56-72
Bacdan
Bacidal
Bacide
Bacin
Bacta
Bacterial
Bacterial [Antibiotic]
Bacticel
Bactin
Bactoprim
Bactramin
Bactrim
Bactrim DS
Bactrim Pediatric
Baktar
Bencole
Bethaprim
Biosulten
Briscotrim
C01965
CAS-738-70-5
CCRIS 2410
CHEBI:45924
CHEMBL22
CID5578
CPD0-1581
CPD000035999
Chemotrim
Chemotrin
Cidal
Co-Trimoxizole
Co-trimoxazole
Colizole
Colizole DS
Comox
Conprim
Cotrim
Cotrim D.S.
Cotrimel
D00145
D014295
DB00440
Deprim
DivK1c_000589
Drylin
Duocide
EINECS 212-006-2
EU-0101271
Esbesul
Espectrin
Euctrim
Eusaprim
Exbesul
Fectrim
Fermagex
Fortrim
Futin
Gantaprim
Gantrim
HMS1568J17
HMS1921I03
HMS2090D14
HMS2092A10
HMS501N11
HSDB 6781
I06-0086
IDI1_000589
Idotrim
Ikaprim
Imexim
Instalac
Ipral
KBio1_000589
KBio2_000647
KBio2_003215
KBio2_005783
KBio3_001465
KBioGR_000863
KBioSS_000647
KSC-4-158
KUC103659N
Kepinol
Kombinax
LS-1627
Lagatrim
Lagatrim Forte
Laratrim
Lastrim
Lidaprim
Linaris
Lopac-T-7883
Lopac0_001271
MLS000079023
MLS001201740
MLS002303068
Methoprim
Metoprim
Microtrim
MolPort-001-826-685
Monoprim
Monotrim
Monotrimin
NCGC00016055-01
NCGC00016055-02
NCGC00016055-06
NCGC00016055-12
NCGC00024707-01
NCGC00024707-03
NCGC00024707-04
NCGC00024707-05
NCGC00024707-06
NCGC00024707-07
NCGC00024707-08
NIH 204
 
NIH 204 (VAN)
NINDS_000589
NSC 106568
NSC-106568
NSC106568
Nopil
Novotrimel
Omstat
Oprea1_495058
Oraprim
Pancidim
Polytrim
Prestwick0_000208
Prestwick1_000208
Prestwick2_000208
Prestwick3_000208
Prestwick_485
Priloprim
Primosept
Primsol
Proloprim
Proloprim (TN)
Protrin
Purbal
Resprim
Resprim Forte
Roubac
Roubal
SAM002264649
SMP2_000262
SMR000035999
SPBio_000874
SPBio_002116
SPECTRUM1500595
STK177322
Salvatrim
Septra
Septra DS
Septra Grape
Septrin
Septrin DS
Septrin Forte
Septrin S
Setprin
Sigaprim
Sinotrim
Smz-Tmp
Spectrum2_000937
Spectrum3_000643
Spectrum4_000372
Spectrum5_001559
Spectrum_000167
Stopan
Streptoplus
Sugaprim
Sulfamar
Sulfamethoprim
Sulfamethoprim-DS
Sulfamethoxazole & Trimethoprim
Sulfatrim
Sulfatrim Pediatric
Sulfatrim-DS
Sulfatrim-SS
Sulfotrim
Sulfoxaprim
Sulmeprim
Sulmeprim Pediatric
Sulprim
Sulthrim
Sultrex
Sumetrolim
Supracombin
Suprim
Syraprim
T 7883
T2286
T7883_SIGMA
TCMDC-125538
TL8005108
TMP/SMX (MIXTURE))
Teleprim
Thiocuran
Tiempe
Tmp-Ratiopharm
Tocris-0650
Toprim
Trigonyl
Trimanyl
Trimesulf
Trimeth/Sulfa
Trimethioprim
Trimethopim(TMP)
Trimethoprim
Trimethoprim & VRC3375
Trimethoprim (JAN/USP/INN)
Trimethoprim [USAN:BAN:INN:JAN]
Trimethoprime
Trimethoprime [INN-French]
Trimethoprimum
Trimethoprimum [INN-Latin]
Trimethopriom
Trimetoprim
Trimetoprim [DCIT]
Trimetoprim [Polish]
Trimetoprima
Trimetoprima [INN-Spanish]
Trimexazole
Trimexol
Trimez-IFSA
Trimezol
Trimogal
Trimono
Trimopan
Trimpex
Trimpex (TN)
Trimpex 200
Triméthoprime
Triprim
Trisul
Trisulcom
Trisulfam
Trisural
U-Prin
UNII-AN164J8Y0X
UPCMLD-DP132
UPCMLD-DP132:001
Unitrim
Uretrim
Uro-D S
Uro-Septra
Urobactrim
Uroplus
Uroplus DS
Uroplus SS
Utetrin
Velaten
WLN: T6N CNJ BZ DZ E1R CO1 DO1 EO1
WR 5949
Wellcoprim
Wellcoprin
Xeroprim
ZINC06627681
Zamboprim
component of Bactrim
component of Septra
nchembio.108-comp1
nchembio.215-comp11
nchembio.221-comp23
trimethoprim
36
PancrelipaseapprovedPhase 2, Phase 3, Phase 197053608-75-6
Synonyms:
1,4-alpha-D- glucan glucanohydrolase
PA
 
Pancreatic alpha-amylase precursor
Pancrelipase (amylase
lipase
protease)
37
GemcitabineapprovedPhase 3, Phase 2201895058-81-460750
Synonyms:
103882-84-4
122111-03-9
2',2'-DiF-dC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFDC
DFdC
DFdCyd
Folfugem
GEO
Gamcitabine
GemLip
Gemcel
 
Gemcin
Gemcitabin
Gemcitabina
Gemcitabina [INN-Spanish]
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
Gemzar (hydrochloride)
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY-188011
LY188011
NCGC00168784-01
NChemBio.2007.10-comp25
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
ZINC18279854
Zefei
gemcitabine
nchembio.573-comp7
nchembio.90-comp2
38
Topotecanapproved, investigationalPhase 2, Phase 3, Phase 1349119413-54-6, 123948-87-860700
Synonyms:
(4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione
(S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
123948-87-8
9-Dimethylaminomethyl-10-hydroxycamptothecin
9-[(dimethylamino)Methyl]-10-hydroxy-(4S)-camptothecin
AC-11592
AC1L1TQZ
AC1Q6APZ
BSPBio_002348
C11158
C23H23N3O5
CCRIS 8163
CHEBI:107501
CHEBI:46035
CHEMBL84
CID60700
D08618
DB01030
HMS2090B20
HSCI1_000228
Hycamptamine
Hycamptin
Hycamtamine
Hycamtin
Hycamtin (TN)
LS-127395
 
MLS000759456
NCGC00178695-01
NCI60_004771
NCIStruc1_001659
NCIStruc2_001796
NChemBio.2007.10-comp24
NSC609699
SK&F-104864-A
SKF 104864
SKF-104864-A
SKF-S 104864
SMP2_000312
SMP2_000327
SMR000466344
TOPO
TOPOTECAN, HYCAMTIN
TPT
TTC
Topotecan (BAN)
Topotecan Hcl
Topotecan Hydrochloride
Topotecan Lactone
Topotecan Monohydrochloride, (S)-Isomer
Topotecan [INN:BAN]
Topotecan lactone
Topotecane
Topotecane [INN-French]
Topotecanum
Topotecanum [INN-Latin]
UNII-7M7YKX2N15
topotecan
39
Octreotideapproved, investigationalPhase 2, Phase 322383150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
 
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
40
lanreotideapprovedPhase 2, Phase 386108736-35-2
Synonyms:
Lanreotide
 
Lanreotide acetate
Somatuline Depot
41
MechlorethamineapprovedPhase 3, Phase 2, Phase 139751-75-24033
Synonyms:
.Beta.,.beta.'-Dichlorodiethyl-N-methylamine
1, 5-Dichloro-3-methyl-3-azapentane hydrochloride
126-85-2 (N-oxide)
2,2'-Dichloro-N-me
2,2'-Dichloro-N-methyldiethylamine
2,2'-Dichlorodiethyl-methylamine
2,2'-dichloro-N-methyldiethylamine
2-Chloro-N-(2-chloroethyl)-N-methylethanamine
302-70-5 (N-oxide, hydrochloride)
51-75-2
55-86-7 (HYDROCHLORIDE)
AC1L1H9H
Antimit
BRN 0605323
BSPBio_001947
Bis(2-chloroethyl)methylamine
Bis(beta-chloroethyl) methylamine
Bis(beta-chloroethyl)methylamine
C07115
C5H11Cl2N
CCRIS 447
CHEBI:28925
CHEMBL427
CID4033
Carolysine
Caryolysin
Caryolysine
Chloramine (the nitrogen mustard)
Chlorethazine
Chlormethine
Chlormethine (INN)
Chlormethine [INN:BAN]
Chlormethinum [INN-Latin]
Cloramin
Clormetina
Clormetina [INN-Spanish]
D07671
DB00888
Di(2-chloroethyl)methylamine
Dichlor amine
Dichloren
DivK1c_000759
EINECS 200-120-5
ENT-25294
Embechine
Embichin
HMS1920J15
HMS2091B04
HMS502F21
HN-2
HN2
HSDB 5083
I14-8708
IBS-L0033631
IDI1_000759
KBio1_000759
KBio2_001369
KBio2_003937
KBio2_006505
KBio3_001447
 
KBioGR_001448
KBioSS_001369
LS-7559
MBA
Me chloroethamine
Mebichloramine
Mechlorethamine
Mechlorethanamine
Mechloroethamine
Mecloretamina
Mecloretamina [Italian]
Methylbis(2-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methyldi(2-chloroethyl)amine
Mitoxine (*Hydrochloride*)
MolPort-001-785-592
Mustargen
Mustine
Mustine note
Mutagen
N,N-Bis(2-chloroethyl)-N-methylamine
N,N-Bis(2-chloroethyl)methylamine
N,N-Di(chloroethyl)methylamine
N-Lost
N-Methyl lost
N-Methyl-2,2'-dichlorodiethylamine
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis-chloraethylamin
N-Methyl-bis-chloraethylamin [German]
N-Methyl-lost
N-Methyl-lost [German]
N-methyl-bis(2-chloroethyl)amine
NCGC00091835-02
NCGC00091835-03
NCGC00091835-04
NCGC00091835-05
NCI60_041682
NINDS_000759
NSC762
Nitol (*Hydrochloride*)
Nitrogen mustard
Nitrogen mustard (HN-2)
Nitrogranulogen
SPBio_000496
SPECTRUM1500375
Spectrum2_000448
Spectrum3_000484
Spectrum4_000924
Spectrum5_001702
Spectrum_000889
Stickstofflost (*Hydrochloride*)
Stickstofflost (ebewe)
T 1024
T-1024
TL 146
UNII-50D9XSG0VR
beta,Beta'-dichlorodiethyl-N-methylamine
beta,beta'-Dichlorodiethyl-N-methylamine
mechlorethamine
thyldiethylamine
β,β'-dichlorodiethyl-N-methylamine
42
IfosfamideapprovedPhase 3, Phase 2, Phase 14003778-73-23690
Synonyms:
(+-)-Ifosfamid
(+-)-Ifosphamide
(+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
(D,L)-Ifosfamide
(R,S)-Ifosphamide
(R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd
2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI)
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
3,} 2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
36341-88-5
3778-73-2
84711-20-6
A 4942
AB00513932
AC-2113
AC1L1GHW
ASTA Z 4942
Ambap3778-73-2
Asta Z 4942
BPBio1_000865
BRN 0611835
BSPBio_000785
C07047
CAS-3778-73-2
CCRIS 352
CHEBI:5864
CHEMBL1024
CID3690
Cyfos
D00343
D007069
DB01181
EINECS 223-237-3
HMS1570H07
HMS2090M12
HMS2093N07
HSDB 7023
Holoxan
Holoxan 1000
I-Phosphamide
I06-0494
IFEX (TN)
Ifex
Ifosfamid
Ifosfamida
Ifosfamida [INN-Spanish]
Ifosfamide (JAN/USP/INN)
 
Ifosfamide Sterile
Ifosfamide [USAN:INN:BAN:JAN]
Ifosfamidum
Ifosfamidum [INN-Latin]
Ifosphamide
Ifsofamide
Iphosphamid
Iphosphamid(e)
Iphosphamide
Iso Endoxan
Iso-Endoxan
Isoendoxan
Isofosfamide
Isophosphamide
Isosfamide
LS-102
LS-99799
MJF 9325
MJF-9325
MLS002154021
Mitoxana
Mitoxana, Ifex, Ifosfamide
MolPort-003-666-704
N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide
N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine
NCGC00016639-01
NCGC00179435-01
NCI-C01638
NCI60_000233
NPFAPI-04
NSC 109,724
NSC 109724
NSC-109,724
NSC-109724
NSC109,724
NSC109724
Naxamide
Prestwick0_000833
Prestwick1_000833
Prestwick2_000833
Prestwick3_000833
S1302_Selleck
SMR001233348
SPBio_002706
STL058690
UNII-UM20QQM95Y
WLN: T6NPOTJ AM2G BO B2G
Z 4942
Z-4942
Z4942
ifosfamide
isosfamide
{3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,
43
SomatostatinapprovedPhase 2, Phase 323738916-34-6, 51110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
44
EpirubicinapprovedPhase 3, Phase 239456420-45-241867
Synonyms:
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione
4'-Epi-DXR
4'-Epiadriamycin
4'-Epidoxorubicin
4'-epi-DX
4'-epi-Doxorubicin
4'-epidoxorubicin
4-Epidoxorubicin
56390-09-1
56390-09-1 (hydrochloride)
56420-45-2
57918-25-9
AC1L26NP
AC1Q6JIV
BRN 1445813
C11230
C27H29NO11
CCRIS 2261
CHEBI:47898
CHEMBL417
CID41867
D07901
DB00445
Ellence
Epi-DX
Epi-Dx
Epiadriamycin
Epidoxorubicin
Epirubicin
 
Epirubicin (INN)
Epirubicin [INN:BAN]
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin (TN)
HSDB 6962
IMI 28
LS-187190
LS-93992
MLS000759412
NChemBio.2007.10-comp15
NSC 256942
NSC-256942
NSC256942
Pharmorubicin Pfs
Pidorubicin
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
SMR000466308
Triferric doxorubicin
UNII-3Z8479ZZ5X
WP 697
45
LenograstimapprovedPhase 3, Phase 2, Phase 11220135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
46
CisplatinapprovedPhase 3, Phase 2, Phase 1277015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
47
Minocyclineapproved, investigationalPhase 323110118-90-85281021
Synonyms:
(2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10118-90-8
13614-98-7 (mono-hydrochloride)
4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
4708-96-7
7-Dimethylamino-6-demethyl-6-deoxytetracycline
AC1NQXWM
Alti-Minocycline
Apo-Minocycline
Arestin
BRN 3077644
Bio-0062
Borymycin
C07225
C23H27N3O7
CHEBI:50694
CHEBI:529981
CHEMBL1434
CHEMBL259172
CID5281021
CL 59806
CRL-1605 & Minocycline
D05045
Dynacin
Gen-Minocycline
HMS2090D03
HSDB 3130
Klinomycin
 
LMPK07000002
LS-93850
Lactoferrin B & Minocycline
Lactoferrin H & Minocycline
MINO
MIY
Minociclina
Minociclina [INN-Spanish]
Minociclinum
Minocin
Minocin (Hydrochloride)
Minocline
Minocyclin
Minocycline (USAN/INN)
Minocycline HCl
Minocycline Monohydrochloride
Minocycline [USAN:BAN:INN]
Minocyclinum
Minocyclinum [INN-Latin]
Minocyn
Minomycin
NCGC00178854-01
NSC 141993
NSC141993
Novo-Minocycline
Solodyn
UNII-FYY3R43WGO
Vectrin
Vectrin (Hydrochloride)
minociclinum
minocycline
nchembio.559-comp1
48
MetforminapprovedPhase 2, Phase 31803657-24-914219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMGG
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
49
OlaparibapprovedPhase 2, Phase 3140763113-22-023725625
Synonyms:
4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
763113-22-0
937799-91-2
AKOS005145764
AZD 2281
AZD-2281
AZD2281
 
Acylpiperazine analogue, 47
CHEMBL521686
EC-000.2324
EN002690
FT-0083489
KU-0059436
KU-59436
Olaparib
Olaparib, KU-0059436, AZD2281, KU0059436, AZD2281
S1060_Selleck
olaparib
50
PembrolizumabapprovedPhase 3, Phase 2, Phase 15071374853-91-4
Synonyms:
Keytruda
 
MK-3475
lambrolizumab

Interventional clinical trials:

(show top 50)    (show all 405)
idNameStatusNCT IDPhase
1Interleukin-2 in Treating Patients With Metastatic Kidney CancerCompletedNCT00006864Phase 4
2Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF TherapyRecruitingNCT02570789Phase 4
3Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic FactorsRecruitingNCT02700568Phase 4
4First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell CarcinomaRecruitingNCT01521715Phase 4
5A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell CancerRecruitingNCT02982954Phase 4
6A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell CarcinomaActive, not recruitingNCT02596035Phase 4
7Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell CarcinomaTerminatedNCT00930345Phase 4
8Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00262847Phase 3
9Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial CancerCompletedNCT00006011Phase 3
10Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial CancerCompletedNCT00003749Phase 3
11TroVax Renal Immunotherapy Survival TrialCompletedNCT00397345Phase 3
12Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial CancerCompletedNCT00005583Phase 3
13Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone SurgeryCompletedNCT00002807Phase 3
14Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial CancerCompletedNCT00006027Phase 3
15Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial CancerCompletedNCT00002493Phase 3
16Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-AntibodyCompletedNCT00606632Phase 3
17A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With NephrectomyCompletedNCT00738530Phase 3
18Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney CancerCompletedNCT00087022Phase 3
19Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)CompletedNCT00072046Phase 3
20Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney TumorsCompletedNCT00002610Phase 3
21Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity CancerCompletedNCT00483782Phase 3
22Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial CancerCompletedNCT00002568Phase 3
23Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal CancerCompletedNCT00002717Phase 3
24Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian CancerCompletedNCT00003644Phase 3
25Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian CancerCompletedNCT00003322Phase 3
26Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
27Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By SurgeryCompletedNCT00326898Phase 3
28Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney CancerCompletedNCT00002611Phase 3
29Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney CancerCompletedNCT00492258Phase 3
30Capecitabine and Oxaliplatin or Standard Follow-Up Care in Treating Patients Who Have Undergone Surgery for Locally Advanced Rectal CancerCompletedNCT00427713Phase 3
31Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue SarcomaCompletedNCT00002764Phase 3
32Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue SarcomaCompletedNCT00002641Phase 3
33Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell CancerCompletedNCT00678392Phase 3
34GH, IGF-I and Somatostatin Analogues in Hepatocellular CarcinomaCompletedNCT00495846Phase 2, Phase 3
35Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and TaxolRecruitingNCT02501954Phase 3
36Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube CancerRecruitingNCT00565851Phase 3
37Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerRecruitingNCT00719303Phase 3
38Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerRecruitingNCT02502266Phase 2, Phase 3
39Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerRecruitingNCT02446600Phase 3
40Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial CancerRecruitingNCT02065687Phase 2, Phase 3
41Zirconium-89-girentuximab PET/CT Imaging in Renal Cell CarcinomaRecruitingNCT02883153Phase 2, Phase 3
42Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers DiscoveryRecruitingNCT02535351Phase 3
43Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After SurgeryRecruitingNCT01575548Phase 3
44Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing NephrectomyRecruitingNCT03055013Phase 3
45Minocycline Attenuate Postoperative Cognitive Dysfunction and DeliriumRecruitingNCT02928692Phase 3
46Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial CancerActive, not recruitingNCT00942357Phase 3
47Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube CancerActive, not recruitingNCT00108745Phase 3
48Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial CancerActive, not recruitingNCT00807768Phase 3
49Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial CancerActive, not recruitingNCT00411138Phase 3
50Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical CancerActive, not recruitingNCT01672892Phase 3

Search NIH Clinical Center for Clear Cell Adenocarcinoma


Cochrane evidence based reviews: adenocarcinoma, clear cell

Genetic Tests for Clear Cell Adenocarcinoma

About this section

Anatomical Context for Clear Cell Adenocarcinoma

About this section

MalaCards organs/tissues related to Clear Cell Adenocarcinoma:

36
Cervix, Ovary, Colon, Prostate, Uterus, Kidney, Tongue

Publications for Clear Cell Adenocarcinoma

About this section

Articles related to Clear Cell Adenocarcinoma:

(show top 50)    (show all 405)
idTitleAuthorsYear
1
The Prostate in Female? Clear Cell Adenocarcinoma in a Female Urethral Diverticulum. (27789300)
2017
2
A clear cell adenocarcinoma of the gallbladder with hepatoid differentiation: case report and review of literature. (27703378)
2016
3
Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary. (27699033)
2016
4
Clear Cell Adenocarcinoma of the Female Urethra: Four Case Presentations of a Clinical and Pathological Entity Requiring Radical Surgery. (26807736)
2016
5
Clear cell adenocarcinoma of the cervix in a ten-year-old girl without prenatal diethylstilbestrol exposure. (27549741)
2016
6
Vesical clear cell adenocarcinoma arising from endometriosis: A mullerian tumor, indistinguishable from ovarian clear cell adenocarcinoma. (27660815)
2016
7
Primary Fallopian Tube Clear Cell Adenocarcinoma in Pregnancy: Case Presentation and Review of the Literature. (26090245)
2015
8
Low Expression of S100P Is Associated With Poor Prognosis in Patients With Clear Cell Adenocarcinoma of the Ovary. (26397155)
2015
9
A rare case of primary clear-cell adenocarcinoma of the bladder arising from bladder endometriosis. (25642923)
2015
10
Late recurrence in a case of vaginal clear cell adenocarcinoma unrelated to transplacental diethylstilbestrol exposure. (26905123)
2015
11
Clear cell adenocarcinoma of the urethra: review of the literature. (25685552)
2015
12
Clear cell adenocarcinoma of the bladder with intravesical cervical invasion. (26109625)
2015
13
High-dose-rate brachytherapy - a novel treatment approach for primary clear cell adenocarcinoma of male urethra. (26207115)
2015
14
Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma. (25658832)
2015
15
Clear cell adenocarcinoma arising from adenomyotic cyst: A case report and literature review. (26530432)
2015
16
Successful radiotherapy for repeated recurrent uterine clear cell adenocarcinoma. (26310385)
2015
17
Clear Cell Adenocarcinoma Arising from Adenofibroma in a Patient with Endometriosis of the Ovary. (26498012)
2015
18
Combined benign Brenner tumor and clear cell adenocarcinoma of the ovary. (26150073)
2015
19
Primary clear cell adenocarcinoma of the colon: a case report and review. (25311456)
2014
20
Splenic metastasis of ovarian clear cell adenocarcinoma: A case report and review of the literature. (24669262)
2014
21
Defect of tropomyosin-related kinase B isotype expression in ovarian clear cell adenocarcinoma. (24815386)
2014
22
Immunohistochemical and molecular features of primary clear cell-adenocarcinoma of the rectum, as predictive factors for individualized therapy. (25178336)
2014
23
A case of clear cell adenocarcinoma arising from endometriosis of the rectum treated by laparoscopic surgery. (25460452)
2014
24
Napsin A is a specific marker for ovarian clear cell adenocarcinoma. (24721826)
2014
25
Primary non-clear-cell adenocarcinoma of the vagina in a diethylstilbestrol exposed woman. (24690973)
2014
26
Clear cell adenocarcinoma of the colon: a case report and review of the literature. (24716050)
2014
27
Clear Cell Adenocarcinoma of the Urethra: 18F-FDG PET/CT Imaging. (25140553)
2014
28
Clear Cell Adenocarcinoma Arising in an Adenomyoma of the Broad Ligament. (24942896)
2014
29
Primary clear cell adenocarcinoma of the peritoneum presents as Sister Mary Joseph's nodule: a case report and literature review. (25556287)
2014
30
Mass Spectrometric Analysis of the Phosphorylation Levels of the SWI/SNF Chromatin Remodeling/Tumor Suppressor Proteins ARID1A and Brg1 in Ovarian Clear Cell Adenocarcinoma Cell Lines. (25083560)
2014
31
Primary clear cell adenocarcinoma of the colon presenting as a huge extracolic mass: A case report. (25202428)
2014
32
Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary. (25010038)
2014
33
Non-diethylstilbestrol exposed vaginal clear cell adenocarcinoma has a common molecular profile with ovarian clear cell adenocarcinoma: A case report. (26082939)
2014
34
Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma simulating fetal gut in a postmenopausal woman. (24707459)
2014
35
Clear Cell Adenocarcinoma of the Prostate: A Rare Oncologic Entity in a 42-Year-Old African American Man. (25217452)
2014
36
Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice. (25398420)
2014
37
Primary Urethral Clear-Cell Adenocarcinoma: Comprehensive Analysis by Surgical Pathology, Cytopathology, and Next-Generation Sequencing. (24389164)
2014
38
Cervical clear cell adenocarcinoma infected with human papillomavirus type 18 in an adolescent. (23849091)
2014
39
Maximum standardized uptake value of fluorodeoxyglucose positron emission tomography/computed tomography is a prognostic factor in ovarian clear cell adenocarcinoma. (24987918)
2014
40
Clear cell adenocarcinoma present exclusively within endometrial polyp: report of two cases. (24817975)
2014
41
Therapy of a clear cell adenocarcinoma of unknown primary arising in the abdominal wall after cesarean section and after hysterectomy. (25301100)
2014
42
Patterns of recurrence and role of pelvic radiotherapy in ovarian clear cell adenocarcinoma. (25275661)
2014
43
Clear cell adenocarcinoma of the abdominal wall: a case report. (24937978)
2014
44
Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. (24504419)
2014
45
Clear cell adenocarcinoma of the peritoneum: a case report and literature review. (25366349)
2014
46
Primary clear cell adenocarcinoma arising from rectal endometriosis. (23362987)
2013
47
Vaginal laparoscopically assisted radical trachelectomy in cervical clear cell adenocarcinoma. (24244219)
2013
48
Expression of chromobox homolog 7 (CBX7) is associated with poor prognosis in ovarian clear cell adenocarcinoma via TRAIL-induced apoptotic pathway regulation. (24375438)
2013
49
An autopsy case of clear cell adenocarcinoma of the urinary bladder. (22024991)
2013
50
Histology and immunohistochemistry of clear cell adenocarcinoma of the urethra: histogenesis and diagnostic problems. (23307189)
2013

Variations for Clear Cell Adenocarcinoma

About this section

Copy number variations for Clear Cell Adenocarcinoma from CNVD:

6
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
12186937116312458116438439AmplificationMETClear cell adenocarcinoma
2266962Y174481503174538309DuplicationAZFClear cell adenocarcinoma

Expression for genes affiliated with Clear Cell Adenocarcinoma

About this section
Search GEO for disease gene expression data for Clear Cell Adenocarcinoma.

Pathways for genes affiliated with Clear Cell Adenocarcinoma

About this section

Pathways related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 47)
idSuper pathwaysScoreTop Affiliating Genes
19.9SMAD3, SMAD4
29.7KLK3, SMAD3, SMAD4
39.5PAX2, PAX8
49.4SMAD3, SMAD4, TP53
59.4SMAD3, SMAD4, TP53
69.4SMAD3, SMAD4, TP53
79.4SMAD3, SMAD4, TP53
8
Show member pathways
9.3SMAD2, SMAD3, SMAD4
9
Show member pathways
9.3SMAD2, SMAD3, SMAD4
109.3SMAD2, SMAD3, SMAD4
11
Show member pathways
9.3SMAD2, SMAD3, SMAD4
12
Show member pathways
9.3SMAD2, SMAD3, SMAD4
139.3SMAD2, SMAD3, SMAD4
14
Show member pathways
9.3SMAD2, SMAD3, SMAD4
159.3SMAD2, SMAD3, SMAD4
16
Show member pathways
9.3SMAD2, SMAD3, SMAD4
179.3SMAD2, SMAD3, SMAD4
189.3SMAD2, SMAD3, SMAD4
199.3SMAD2, SMAD3, SMAD4
20
Show member pathways
9.3SMAD2, SMAD3, SMAD4
219.3SMAD2, SMAD3, SMAD4
22
Show member pathways
9.3SMAD2, SMAD3, SMAD4
239.3SMAD2, SMAD3, SMAD4
24
Show member pathways
9.3SMAD2, SMAD3, SMAD4
25
Show member pathways
9.3SMAD2, SMAD3, SMAD4
269.3SMAD2, SMAD3, SMAD4
279.3SMAD2, SMAD3, SMAD4
289.0SMAD2, SMAD3, TP53
29
Show member pathways
9.0HNF1B, SMAD2, SMAD3, SMAD4
308.9ESR1, SMAD4, TP53
318.8PAX2, SMAD2, SMAD3, SMAD4
32
Show member pathways
8.8SMAD2, SMAD3, SMAD4, TP53
33
Show member pathways
8.8SMAD2, SMAD3, SMAD4, TP53
348.8SMAD2, SMAD3, SMAD4, TP53
35
Show member pathways
8.8SMAD2, SMAD3, SMAD4, TP53
36
Show member pathways
8.8SMAD2, SMAD3, SMAD4, TP53
378.8SMAD2, SMAD3, SMAD4, TP53
388.8SMAD2, SMAD3, SMAD4, TP53
39
Show member pathways
8.8SMAD2, SMAD3, SMAD4, TP53
40
Show member pathways
8.8SMAD2, SMAD3, SMAD4, TP53
41
Show member pathways
8.7HNF1B, PTHLH, SMAD2, SMAD3, SMAD4
428.5ESR1, SMAD2, SMAD3, SMAD4
43
Show member pathways
8.5ESR1, SMAD2, SMAD3, SMAD4
448.5ESR1, SMAD2, SMAD3, SMAD4
458.2ESR1, SMAD2, SMAD4, TP53
468.0KLK3, PAX8, SMAD2, SMAD3, SMAD4, TP53
47
Show member pathways
8.0ESR1, SMAD2, SMAD3, SMAD4, TP53

GO Terms for genes affiliated with Clear Cell Adenocarcinoma

About this section

Cellular components related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1activin responsive factor complexGO:003244410.4SMAD2, SMAD4
2SMAD2-SMAD3 protein complexGO:007114410.2SMAD2, SMAD3
3SMAD protein complexGO:00711419.9SMAD2, SMAD3, SMAD4
4transcription factor complexGO:00056679.0HNF1B, SMAD2, SMAD3, SMAD4
5nuclear chromatinGO:00007908.4ARID1A, ESR1, SMAD2, SMAD3, SMAD4, TP53
6protein complexGO:00432348.1ESR1, KLK3, PAX2, SMAD2, SMAD3, TP53
7nucleoplasmGO:00056547.2ARID1A, ESR1, HNF1B, PAX8, PTHLH, SMAD2
8nucleusGO:00056346.4ARID1A, ESR1, HNF1B, KLK3, PAX2, PAX8

Biological processes related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 54)
idNameGO IDScoreTop Affiliating Genes
1regulation of transforming growth factor beta2 productionGO:003290910.7SMAD3, SMAD4
2osteoblast developmentGO:000207610.7PTHLH, SMAD3
3nephric duct formationGO:007217910.5HNF1B, PAX2
4positive regulation of pri-miRNA transcription from RNA polymerase II promoterGO:190289510.5SMAD3, TP53
5mesonephric tubule developmentGO:007216410.5HNF1B, PAX8
6thyroid gland developmentGO:003087810.4PAX8, SMAD3
7activin receptor signaling pathwayGO:003292410.4SMAD2, SMAD3
8embryonic foregut morphogenesisGO:004861710.4SMAD2, SMAD3
9embryonic pattern specificationGO:000988010.4SMAD2, SMAD3
10nodal signaling pathwayGO:003809210.4SMAD2, SMAD3
11paraxial mesoderm morphogenesisGO:004834010.4SMAD2, SMAD3
12pericardium developmentGO:006003910.4SMAD2, SMAD3
13primary miRNA processingGO:003105310.4SMAD2, SMAD3
14signal transduction involved in regulation of gene expressionGO:002301910.3SMAD2, SMAD3
15mesenchymal to epithelial transition involved in metanephros morphogenesisGO:000333710.3PAX2, PAX8
16mesonephros developmentGO:000182310.3PAX2, PAX8
17metanephric distal convoluted tubule developmentGO:007222110.3PAX2, PAX8
18metanephric epithelium developmentGO:007220710.3PAX2, PAX8
19metanephric nephron tubule formationGO:007228910.3PAX2, PAX8
20negative regulation of apoptotic process involved in metanephric collecting duct developmentGO:190021510.3PAX2, PAX8
21negative regulation of apoptotic process involved in metanephric nephron tubule developmentGO:190021810.3PAX2, PAX8
22negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesisGO:007230510.3PAX2, PAX8
23positive regulation of branching involved in ureteric bud morphogenesisGO:009019010.3PAX2, PAX8
24positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesisGO:007210810.3PAX2, PAX8
25positive regulation of metanephric DCT cell differentiationGO:200059410.3PAX2, PAX8
26pronephric field specificationGO:003900310.3PAX2, PAX8
27regulation of metanephric nephron tubule epithelial cell differentiationGO:007230710.3PAX2, PAX8
28negative regulation of cell growthGO:003030810.2SMAD3, SMAD4, TP53
29kidney developmentGO:000182210.2HNF1B, PAX8, SMAD4
30developmental growthGO:004858910.1SMAD2, SMAD3, SMAD4
31positive regulation of epithelial to mesenchymal transitionGO:001071810.1SMAD2, SMAD3, SMAD4
32anterior/posterior pattern specificationGO:000995210.1HNF1B, SMAD2, SMAD4
33intracellular estrogen receptor signaling pathwayGO:003052010.1ARID1A, ESR1
34regulation of bindingGO:005109810.1SMAD2, SMAD3, SMAD4
35regulation of transforming growth factor beta receptor signaling pathwayGO:001701510.1SMAD2, SMAD3, SMAD4
36SMAD protein complex assemblyGO:000718310.1SMAD2, SMAD3, SMAD4
37SMAD protein signal transductionGO:006039510.1SMAD2, SMAD3, SMAD4
38branching involved in ureteric bud morphogenesisGO:000165810.1PAX2, PAX8, SMAD4
39negative regulation of mesenchymal cell apoptotic process involved in metanephros developmentGO:190021210.0HNF1B, PAX2, PAX8
40pronephros developmentGO:004879310.0HNF1B, PAX2, PAX8
41endoderm developmentGO:00074929.8HNF1B, SMAD2, SMAD3, SMAD4
42urogenital system developmentGO:00016559.8PAX2, PAX8
43gastrulationGO:00073699.8ARID1A, SMAD2, SMAD3, SMAD4
44transforming growth factor beta receptor signaling pathwayGO:00071799.7SMAD2, SMAD3, SMAD4
45positive regulation of gene expressionGO:00106289.6HNF1B, SMAD2, SMAD3, TP53
46uterus developmentGO:00600659.4ESR1, SMAD4
47negative regulation of cell proliferationGO:00082859.3PTHLH, SMAD2, SMAD3, SMAD4, TP53
48protein deubiquitinationGO:00165798.8ESR1, SMAD2, SMAD3, SMAD4, TP53
49negative regulation of transcription from RNA polymerase II promoterGO:00001228.1ARID1A, ESR1, HNF1B, SMAD2, SMAD3, SMAD4
50transcription from RNA polymerase II promoterGO:00063668.0ESR1, PAX2, PAX8, SMAD2, SMAD4, TP53

Molecular functions related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 18)
idNameGO IDScoreTop Affiliating Genes
1transcription factor activity, protein bindingGO:000098810.7SMAD3, SMAD4
2co-SMAD bindingGO:007041010.4SMAD2, SMAD3
3I-SMAD bindingGO:007041110.4SMAD2, SMAD4
4enhancer bindingGO:003532610.3SMAD2, SMAD3
5primary miRNA bindingGO:007087810.3SMAD2, SMAD3
6core promoter proximal region sequence-specific DNA bindingGO:000098710.3PAX2, SMAD3, SMAD4
7R-SMAD bindingGO:007041210.1SMAD2, SMAD3, SMAD4
8RNA polymerase II regulatory region sequence-specific DNA bindingGO:00009779.9HNF1B, SMAD3, SMAD4, TP53
9transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activityGO:00306189.6SMAD2, SMAD3
10protein heterodimerization activityGO:00469829.2HNF1B, SMAD2, SMAD3, SMAD4, TP53
11sequence-specific DNA bindingGO:00435659.0ESR1, HNF1B, PAX8, SMAD3, SMAD4
12chromatin bindingGO:00036828.8ESR1, SMAD2, SMAD3, SMAD4, TP53
13transcription regulatory region DNA bindingGO:00442128.7HNF1B, PAX2, PAX8, SMAD3, SMAD4, TP53
14RNA polymerase II core promoter proximal region sequence-specific DNA bindingGO:00009788.7ESR1, PAX8, SMAD2, SMAD3, SMAD4
15transcription factor bindingGO:00081348.4ESR1, PAX2, SMAD2, SMAD3, TP53
16transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific bindingGO:00010778.4ESR1, PAX8, SMAD2, SMAD4
17transcription factor activity, sequence-specific DNA bindingGO:00037007.8ESR1, HNF1B, PAX8, SMAD2, SMAD3, SMAD4
18DNA bindingGO:00036777.1ARID1A, ESR1, HNF1B, PAX2, PAX8, SMAD2

Sources for Clear Cell Adenocarcinoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet